Geneos Wealth Management’s Alaunos Therapeutics TCRT Stock Holding History

Geneos Wealth Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	–	–	2534
2022 Q2	$0	Buy	+3	New	+$287	﹤0.01%	2786
2021 Q3	–	Sell	-3	Closed	-$1K	–	2904
2021 Q2	$1K	Sell	3 -13	-81%	-$6.07K	﹤0.01%	2802
2021 Q1	$8K	Hold	16	–	–	﹤0.01%	2500
2020 Q4	$9K	Hold	16	–	–	﹤0.01%	2273
2020 Q3	$6K	Hold	16	–	–	﹤0.01%	2138
2020 Q2	$8K	Sell	16 -1	-6%	-$446	﹤0.01%	2007
2020 Q1	$6K	Hold	17	–	–	﹤0.01%	1998
2019 Q4	$12K	Hold	17	–	–	﹤0.01%	1906
2019 Q3	$10K	Hold	17	–	–	﹤0.01%	1903
2019 Q2	$14K	Hold	17	–	–	﹤0.01%	1790
2019 Q1	$9K	Hold	17	–	–	﹤0.01%	1878
2018 Q4	$4K	Hold	17	–	–	﹤0.01%	2072
2018 Q3	$7K	Hold	17	–	–	﹤0.01%	1989
2018 Q2	$7K	Hold	17	–	–	﹤0.01%	1849
2018 Q1	$9K	Buy	17 +1	+6%	+$623	﹤0.01%	1692
2017 Q4	$10K	Hold	16	–	–	﹤0.01%	1642
2017 Q3	$15K	Hold	16	–	–	﹤0.01%	1439
2017 Q2	$15K	Buy	16 +3	+23%	+$2.94K	﹤0.01%	1388
2017 Q1	$12K	Hold	13	–	–	﹤0.01%	1431
2016 Q4	$10K	Hold	13	–	–	﹤0.01%	1435
2016 Q3	$11K	Hold	13	–	–	﹤0.01%	1344
2016 Q2	$11K	Sell	13 -5	-28%	-$5.44K	﹤0.01%	1303
2016 Q1	$20K	Buy	+18	New	+$18.4K	﹤0.01%	1093

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geneos Wealth Management's TCRT Position: Q3 2022 in Review

Geneos Wealth Management sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 3 shares.

Geneos Wealth Management first reported a position in TCRT in Q1 2016 and held it in 23 quarters. The position peaked at $20K in Q1 2016. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

Geneos Wealth Management reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 3 Alaunos Therapeutics shares in Q3 2022.
Geneos Wealth Management first reported a position in Alaunos Therapeutics in Q1 2016 and held it in 23 quarters.
Geneos Wealth Management's Alaunos Therapeutics position peaked at $20K in Q1 2016.
125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.